share_log

Evercore ISI Group Maintains Outperform on Heron Therapeutics, Lowers Price Target to $10

Evercore ISI Group Maintains Outperform on Heron Therapeutics, Lowers Price Target to $10

Evercore ISI 集团维持Heron Therapeutics的跑赢大盘,将目标股价下调至10美元
Benzinga ·  2023/03/24 11:53

Evercore ISI Group analyst Shweta Khajuria maintains Heron Therapeutics (NASDAQ:HRTX) with a Outperform and lowers the price target from $15 to $10.

Evercore ISI Group分析师Shweta Khajuria维持Heron Therapeutics(纳斯达克股票代码:HRTX)跑赢大盘,并将目标股价从15美元下调至10美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发